



## **Synta Pharmaceuticals to Present at BIO CEO & Investor Conference February 12**

February 8, 2007

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Safi Bahcall, Ph.D., President and CEO, will discuss the Company's oncology and inflammation drug discovery and development programs and provide a general corporate overview at the upcoming BIO CEO & Investor Conference, to be held at the Waldorf Astoria Hotel in New York City. The presentation will begin at 2:00 p.m. (EST) on Monday, February 12, 2007, and will be located in the Park Avenue Suite Center/North.

The presentation will be available via live audio webcast on the Company's website at [www.syntapharma.com](http://www.syntapharma.com).

### About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. For more information, please see [www.syntapharma.com](http://www.syntapharma.com).

### Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" beginning on page 11 of our Registration Statement on Form S-1 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Synta Pharmaceuticals Corp.  
Rob Kloppenburg, 781-541-7125  
or  
MacDougall Biomedical Communications  
Doug MacDougall, 508-647-0209

SOURCE: Synta Pharmaceuticals Corp.